tradingkey.logo

LivaNova PLC

LIVN
65.930USD
-0.830-1.24%
Close 02/03, 16:00ETQuotes delayed by 15 min
3.60BMarket Cap
LossP/E TTM

LivaNova PLC

65.930
-0.830-1.24%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of LivaNova PLC

Currency: USD Updated: 2026-02-02

Key Insights

LivaNova PLC's fundamentals are relatively very healthy, with industry-average ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 71.76.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

LivaNova PLC's Score

Industry at a Glance

Industry Ranking
1 / 206
Overall Ranking
25 / 4529
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Negative

LivaNova PLC Highlights

StrengthsRisks
LivaNova PLC is a medical technology company. The Company designs, develops, manufactures, markets and sells products and therapies. Its segments include Cardiopulmonary, and Neuromodulation. Its Cardiopulmonary segment is engaged in the design, development, manufacture, marketing, and sale of cardiopulmonary products, including heart-lung machines (HLM), oxygenators, autotransfusion systems, perfusion tubing systems, cannula, and other related accessories. Its Neuromodulation segment is engaged in the design, development, manufacture, marketing, and sale of devices that deliver neuromodulation therapy for treating drug-resistant epilepsy (DRE) and difficult-to-treat depression (DTD). Its principal Neuromodulation product, the VNS Therapy System, consists of an implantable pulse generator and connective lead that stimulates the vagus nerve, surgical equipment to assist with the implant procedure, and equipment and instruction manuals.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.67% year-on-year.
Fairly Valued
The company’s latest PE is -16.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 57.85M shares, decreasing 15.44% quarter-over-quarter.
Held by Joel Greenblatt
Star Investor Joel Greenblatt holds 8.54K shares of this stock.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
71.756
Target Price
+9.20%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-02

The current financial score of LivaNova PLC is 9.08, ranking 16 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 357.75M, representing a year-over-year increase of 12.46%, while its net profit experienced a year-over-year increase of 18.72%.

Score

Industry at a Glance

Previous score
9.08
Change
0

Financials

9.04

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

10.00

Operational Efficiency

9.63

Growth Potential

9.24

Shareholder Returns

7.51

LivaNova PLC's Company Valuation

Currency: USD Updated: 2026-02-02

The current valuation score of LivaNova PLC is 7.03, ranking 133 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -16.76, which is -6093.07% below the recent high of 1004.49 and -964.69% above the recent low of -178.45.

Score

Industry at a Glance

Previous score
7.03
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 1/206
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-02

The current earnings forecast score of LivaNova PLC is 8.18, ranking 53 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 67.50, with a high of 86.00 and a low of 53.32.

Score

Industry at a Glance

Previous score
8.18
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 11 analysts
Buy
Current Rating
71.756
Target Price
+9.20%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

114
Total
6
Median
9
Average
Company name
Ratings
Analysts
LivaNova PLC
LIVN
11
Stryker Corp
SYK
32
Dexcom Inc
DXCM
31
Abbott Laboratories
ABT
31
Medtronic PLC
MDT
31
Zimmer Biomet Holdings Inc
ZBH
30
1
2
3
...
23

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-02

The current price momentum score of LivaNova PLC is 9.29, ranking 12 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 69.65 and the support level at 62.13, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
9.48
Change
-0.19

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(1)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.515
Buy
RSI(14)
66.081
Neutral
STOCH(KDJ)(9,3,3)
85.398
Overbought
ATR(14)
1.698
Low Volatility
CCI(14)
201.933
Overbought
Williams %R
15.426
Overbought
TRIX(12,20)
0.129
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(0)
Neutral(0)
Buy(6)
Indicators
Value
Direction
MA5
65.036
Buy
MA10
64.261
Buy
MA20
63.691
Buy
MA50
62.678
Buy
MA100
58.099
Buy
MA200
51.878
Buy

Institutional Confidence

Currency: USD Updated: 2026-02-02

The current institutional shareholding score of LivaNova PLC is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 105.93%, representing a quarter-over-quarter increase of 1.74%. The largest institutional shareholder is PRIMECAP Management, holding a total of 4.44M shares, representing 8.14% of shares outstanding, with 3.69% decrease in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
6.34M
-0.61%
PRIMECAP Management Company
Star Investors
4.44M
-4.23%
Millennium Management LLC
2.97M
+22.43%
Artisan Partners Limited Partnership
2.43M
+94.54%
Wellington Management Company, LLP
2.35M
+83.51%
The Vanguard Group, Inc.
Star Investors
2.28M
-6.46%
State Street Investment Management (US)
2.06M
-1.24%
Dimensional Fund Advisors, L.P.
1.72M
+6.62%
AQR Capital Management, LLC
1.66M
-19.07%
Geode Capital Management, L.L.C.
1.45M
+1.14%
1
2

Risk Assessment

Currency: USD Updated: 2026-02-02

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of LivaNova PLC is 7.91, ranking 28 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.97. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. LivaNova PLC’s latest ESG disclosure is at an average level in the Healthcare Equipment & Supplies industry, showing no material impact on overall risk.

Score

Industry at a Glance

Previous score
7.91
Change
0
Beta vs S&P 500 index
0.94
VaR
+3.15%
240-Day Maximum Drawdown
+31.62%
240-Day Volatility
+39.36%

Return

Best Daily Return
60 days
+9.35%
120 days
+9.35%
5 years
+23.72%
Worst Daily Return
60 days
-5.80%
120 days
-5.80%
5 years
-15.76%
Sharpe Ratio
60 days
+2.61
120 days
+2.03
5 years
+0.08

Risk Assessment

Maximum Drawdown
240 days
+31.62%
3 years
+47.23%
5 years
+63.48%
Return-to-Drawdown Ratio
240 days
+1.20
3 years
+0.38
5 years
-0.07
Skewness
240 days
+1.93
3 years
+1.56
5 years
+0.90

Volatility

Realised Volatility
240 days
+39.36%
5 years
+39.87%
Standardised True Range
240 days
+2.36%
5 years
+3.00%
Downside Risk-Adjusted Return
120 days
+406.78%
240 days
+406.78%
Maximum Daily Upside Volatility
60 days
+33.62%
Maximum Daily Downside Volatility
60 days
+23.98%

Liquidity

Average Turnover Rate
60 days
+1.21%
120 days
+1.35%
5 years
--
Turnover Deviation
20 days
+20.00%
60 days
+4.03%
120 days
+15.65%

Peer Comparison

Healthcare Equipment & Supplies
LivaNova PLC
LivaNova PLC
LIVN
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
Cencora Inc
COR
8.53 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
AxoGen Inc
AxoGen Inc
AXGN
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LeMaitre Vascular Inc
LeMaitre Vascular Inc
LMAT
8.27 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Edwards Lifesciences Corp
Edwards Lifesciences Corp
EW
8.26 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Varex Imaging Corp
Varex Imaging Corp
VREX
8.25 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI